2024-11-15 - Analysis Report
## Johnson & Johnson (JNJ) Stock Analysis Report

**Company Overview:** Johnson & Johnson is a multinational pharmaceutical, medical devices, and consumer goods company.

**Performance Analysis:**

**1. Relative Performance:**

* **Cumulative Returns:** JNJ has generated a cumulative return of 58.11% compared to the S&P 500 (VOO) return of 179.47%.
* **Performance Gap:** The gap between JNJ and VOO is -121.36% currently, putting JNJ significantly behind the benchmark index. The relative gap puts JNJ in the 29th percentile of its historical performance, indicating it has been consistently underperforming the market.
* **Alpha and Beta Analysis:** The company demonstrates consistent beta levels around 0.7, suggesting a lower volatility compared to the market. However, its alpha has been declining over the past years, indicating a weaker ability to outperform the market. 

**2. Recent Price Movement:**

* **Closing Price:** 153.24 (Last-market: 152.58)
* **Moving Averages:** 
    * 5-day: 154.62
    * 20-day: 159.81
    * 60-day: 162.17
    * The stock is currently trading below its 5-, 20-, and 60-day moving averages, indicating a potential downtrend.

**3. Technical Indicators:**

* **RSI:** 14.93 - This suggests that the stock is currently oversold, making it potentially attractive for long-term investors.
* **PPO:** -0.52 - A negative PPO indicates that the price is below its 12-day moving average, further suggesting potential bearish momentum.
* **Relative Divergence:** -6.21 - The recent 20-day relative divergence is negative, indicating a short-term downward trend.
* **Expected Return:** 0.0% -  This suggests that JNJ is expected to perform in line with the S&P 500 over the long term (2 years or more) for a potential long-term investor.

**4. Recent Earnings & Outlook:**

| Date        | EPS | Revenue |
|-------------|-----|---------|
| 2024-10-23 | 1.12 | 22.47 B$ |
| 2024-07-25 | 1.95 | 22.45 B$ |
| 2024-05-01 | 1.35 | 21.38 B$ |
| 2024-02-16 | 1.68 | 21.39 B$ |
| 2023-10-27 | 10.32| 21.35 B$ | 

* The most recent earnings report (2024-10-23) showed an EPS of 1.12, which was slightly lower than analysts' expectations. However, the company's revenue surpassed analysts' expectations. 
* Overall, JNJ continues to demonstrate consistent revenue growth and stable profitability.

**5. Financial Information:**

**Revenue and Profitability:**

| Quarter     | Revenue    | Profit Margin |
|-------------|------------|---------------|
| 2024-09-30 | $22.47B   | 69.01%        |
| 2024-06-30 | $22.45B   | 69.40%        |
| 2024-03-31 | $21.38B   | 69.55%        |
| 2023-12-31 | $21.39B   | 68.23%        |
| 2023-09-30 | $21.35B   | 69.06%        |

* JNJ consistently demonstrates strong profitability with a high profit margin, reflecting its well-established brand and solid market position.

**Capital and Profitability:**

| Quarter     | Equity   | ROE    |
|-------------|----------|--------|
| 2024-09-30 | $70.16B  | 3.84%  |
| 2024-06-30 | $71.54B  | 6.55%  |
| 2024-03-31 | $70.02B  | 4.65%  |
| 2023-12-31 | $68.77B  | 5.89%  |
| 2023-09-30 | $71.23B  | 36.54% |

* The company maintains a healthy equity position with a generally positive return on equity, demonstrating efficient utilization of capital.

**6. News & Recent Issues:**

* **Recent Earnings News:**
    * The latest earnings report (2024-10-23) was well-received by investors, with the stock price experiencing a slight uptick.
* **Market Outlook:**
    * Recent analyst opinions on JNJ are generally positive, highlighting its strong dividend track record and potential for growth in its pharmaceutical and medical device segments.
* **Performance Highlights:**
    * JNJ continues to hold a dominant position in the consumer healthcare market, benefiting from its diversified product portfolio and global reach.

**7. Overall Analysis:**

JNJ is a well-established, financially sound company with a history of consistent profitability and dividend payments. While its current performance lags behind the S&P 500, it remains a potentially attractive investment for long-term investors seeking a stable and reliable stock with a history of delivering returns over time. JNJ's oversold position and potential for growth in its pharmaceutical and medical device segments make it a potential candidate for consideration. 

**Disclaimer:** This report is for informational purposes only and should not be considered investment advice. 
